top of page

Local governments in Ohio are “unequivocally opposed” to lawmaker-proposed changes to marijuana tax revenue allocations approved by voters in 2023. That’s according to a new study published by the Ohio State University’s (OSU) Moritz College of Law representing 38 municipalities across the state.

When voters legalized adult-use cannabis in 2023, the law they passed included a 36 percent allocation of marijuana tax revenue to local governments that host retail stores. But Republican-led legislation currently before lawmakers would make significant cuts to those funds, which municipal representatives said in the new report could lead to tax increases and layoffs.

Comments from officials surveyed as part of the OSU study indicated that many localities currently plan to use the voter-approved allocations for public safety and infrastructure.

“When it came to how municipalities planned to spend expected marijuana tax revenue, they typically spoke of prioritizing law enforcement, fire, infrastructure maintenance, and parks,” the report says. “They indicated that this revenue would be critical to their ability to maintain public safety and improve the lives of their residents.”

“Similarly, others expressed that they may not want to continue to have recreational sales in their area if the revenue was eliminated,” the report adds, “or that the revenue was part of the original motivation for wanting dispensaries.”

According to the new OSU report, municipalities that host dispensaries are expected under current law to divide roughly $22 million in fiscal year 2025. That’s assuming Ohio hits state revenue of $62 million overall.

In other words, authors wrote, each retail store would generate approximately $175,000 for host communities.

Ohio lawmakers have proposed changing a provision that directs a portion of #marijuana#tax revenue to municipalities that host dispensaries. Our survey asked host localities how these proposed changes would impact their communities. Read their two cents: https://t.co/XCvYSXfBHRpic.twitter.com/oTx3PJLRAz

— Drug Enforcement and Policy Center at Ohio State (@OSULawDEPC) March 18, 2025


Researchers identified 75 localities that Division of Cannabis Control data showed was host to at least one adult-use marijuana retailer, then gathered contact information for 159 officials like mayor and city manager across 73 municipalities.

Overall, 38 localities provided responses to the survey.

“Any revenue we could receive from the marijuana sales would be beneficial in supporting many city services: police and fire protection, street maintenance, and other critical infrastructure projects,” said an official from the city of Ravenna. “These funds would help us improve services for our residents and community and maybe even reduce the need for future tax increases.”

Another, from the city of Monroe, noted that the jurisdiction “was among the first municipalities to embrace the controversial introduction of medical marijuana and adult-use cannabis in a generally oppositional climate.”

“Monroe City Council took this step,” the official told authors, “with the vision that it would likely create a new revenue stream to help deliver services to our residents without imposing any additional burden on them.”

A representative from Euclid expressed similar sentiments: “I would say that part of our decision for allowing marijuana facilities in the community was due to the potential revenue. I view it [as] a broken promise if they change the host community fund provision.”

The city of Milford, meanwhile, reported that expected tax revenue would allow them to maintain “fiscal stability and avoid drastic cuts to vital city services.”

So far three bills have been introduced that would make major changes to the state’s cannabis law. In their current forms, two would amend local tax provisions.

A budget proposal from Gov. Mike DeWine (R) for fiscal years 2026 and 2027 would do away with the municipal allocations entirely. (It would also double the state tax on marijuana, raising it to 20 percent.)

A separate bill, HB 160, would reduce local allocations from 36 percent to 20 percent, and it would sunset the disbursements after five years.

As the OSU report notes, while marijuana revenue has been collected for the current year, it has not been disbursed “because the ballot measure did not include appropriation language. The Ohio legislature could pass an appropriation for these funds at any time but has not yet chosen to do so.”

As of March 10, it continues, the state has collected $37.6 million in marijuana excise tax.

Municipal officials told OSU researchers in the new survey that they felt local communities were best positioned to decide how to spend tax dollars collected for host localities.

“The City strongly feels that decisions on how best to use tax dollars are best made at the local level, where we are providing front-line services to our residents and businesses,” said an official from Lebanon.

Another respondent, from Lorain, wrote: “I see the legislature thinks we didn’t know what we were voting for and are going to help us poor citizens. We do oppose the proposed move by the General Assembly, and the Governor, to once again impact the people’s wishes.”

The OSU study notes that despite the governor’s and GOP lawmaker’s efforts to amend how marijuana tax revenue is spent, they’ve given little explanation for the changes.

“In the case of the various proposed changes to the marijuana tax allocation, the Ohio General Assembly has not provided any policy rationale or reason as to why changes to the voter-approved allocations are needed,” the report says. “Various members of the General Assembly have suggested that voters simply did not understand or care about the specific details of Issue 2 when they voted for it, but the official ballot language that voters considered was quite explicit about the express tax allocations in the initiative.”

“The impacts of the proposed changes to the marijuana tax revenue allocation are significant for local governments and local communities that made decisions about allowing marijuana dispensaries based on the promise of future tax revenue,” it adds. Whether that means cuts to public safety, infrastructure, or parks, or a potential need for future tax increases on local residents, municipal governments are unequivocally opposed to the proposed changes to the original marijuana tax revenue allocation to the Host Community Cannabis Fund.”

The House bill that would affect tax allocations, HB 160, is one of a pair of bills introduced by Ohio Republicans this session that would make major changes to the voter-passed marijuana law. That measure, from Rep. Brian Stewart (R), and another in the Senate—SB 56, from Sen. Steve Huffman (R)—both would also create new limits and criminal penalties around legal marijuana.

SB 56 originally included amendments to local tax allocations but in its current form does not contain tax provisions.

While the Senate bill is seen as stricter in some ways—for example, it would cut in half the number of plants adults could grow under the law—both bills would set THC limits on marijuana products, weaken or eliminate equity provisions and set a 350-shop restriction on retail across the state.

Advocates from drug reform and civil liberties groups held an event last week to encourage pushback on the two measures as well as the governor’s budget bill, with speakers from NORML, the Drug Policy Alliance (DPA), Marijuana Policy Project (MPP) and ACLU of Ohio describing them as efforts to undo the will of voters.

Lawmakers could also still introduce other measures, noted Gary Daniels, chief lobbyist for ACLU of Ohio, and it’s also expected that a sweeping state budget bill could be used to make changes to the cannabis law. For example, an increased cannabis excise tax was introduced and later removed from the Senate bill, but an even steeper tax hike is now in the governor’s budget proposal.

Daniels added that Ohio voters are passionate about cannabis reform. While ACLU works on an array of issues—free speech, religious liberty, LGBT rights—he noted that “it seems that nothing activates Ohioans the same way as this particular issue.”

“The reception is, over the past couple years, much larger, much more robust than any of our other issues,” he said.

Earlier this month, Ohio’s Senate president pushed back against criticism of SB 56, claiming that the legislation does not disrespect the will of the electorate and would have little impact on products available in stores.

“My definitive message is: If you want to go purchase marijuana products from a licensed dispensary, that is going to be unchanged by Senate Bill 56,” Senate President Rob McColley (R) said during a podcast appearance. “The only difference you’ll notice is the packaging may not look as appealing to children, but you’ll still be able to buy the same products.”

Critics in the statehouse, such as Sen. Bill DeMora (D), who spoke against the measure on the Senate floor, said the plan “goes against the will of the voters and will kill the adult industry in Ohio.”

Separately in the legislature this month, Sens. Huffman and Shane Wilkin (R) introduced legislation that would impose a 15 percent tax on intoxicating hemp products and limit their sales to adult-use dispensaries—not convenience stores, smoke shops or gas stations.

“Currently, intoxicating hemp products are untested, unregulated psychoactive products that can be just as intoxicating, if not more intoxicating, than marijuana,” Wilkin said in recent sponsor testimony to the Senate General Government Committee.

DeWine has repeatedly asked lawmakers to regulate or ban intoxicating hemp products such as delta-8 THC.

Ending Drug Testing For Marijuana During Pregnancy ‘Improved Racial Parity’ Without Harming Babies, American Medical Association Study Says

 
 
 

President-elect Donald Trump has announced his intent to nominate physician and Fox News correspondent Janette Nesheiwat to become the next U.S. surgeon general. And as far as marijuana policy is concerned, she’s said that she’s “all for” the use of medical cannabis for certain conditions.

While Nesheiwat’s stance on broader reform is unclear, her social media posts and media appearances signal that she’s at least supportive of allowing access to medical marijuana for patients with conditions like seizure disorders or cancer. However, she’s also promoted research linking cannabis smoking to cardiovascular issues.

Citing a study last year, Nesheiwat said “if you use marijuana—whether you smoke marijuana or vape or use edibles—then you have an increased risk by about 25 percent of developing a heart attack, or about 42 percent increased risk of developing a stroke, which can leave you paralyzed or take your life.”

“Why is this? When you inhale marijuana, for example, you are inhaling particulate matter, which is causing inflammation to the blood vessels—inflammation and irritation to blood vessels to your heart, to your brain and to other organs in your body,” she said. “So you might want to think twice before you light up. Make sure you take care of yourself.”

Do you smoke pot? 🪴 New info published by the American Heart Association found that people who smoke marijuana have a higher risk of heart attack & stroke. 800,00O Americans have a heart attack/stroke each year. Knowing this information, will you quit smoking? pic.twitter.com/bFq7eOgVSN

— Dr Janette Nesheiwat (@DoctorJanette) March 1, 2024


In 2019, she also weighed in on a lung injury crisis that stemmed from contaminated vape cartridges containing “both nicotine and THC, the high-inducing chemical in marijuana.”

Happy #LaborDay! You can catch me on @AmericaNewsroom@FoxNews TODAY @ 10:45am EST— I’ll discuss the hundreds of severe lung injuries that have been reported in #teens and young adults from #vaping both #nicotine and #THC, the high-inducing chemical in #marijuana—Tune in! pic.twitter.com/RjheXWMEKJ

— Dr Janette Nesheiwat (@DoctorJanette) September 2, 2019


But in 2018, she expressed support for the use of medical cannabis, at least for select conditions. In response to a social media post calling for marijuana reform, she said “I’m all for medical marijuana. seizures, cancer patients etc.”

I’m all for medical marijuana. seizures, cancer patients etc

— Dr Janette Nesheiwat (@DoctorJanette) May 9, 2018


In 2021, Nesheiwat seemed to criticize the decision to suspend U.S. runner Sha’Carri Richardson from the Olympics over a positive THC test, challenging the idea that marijuana is a performance enhancing drug.

“Marijuana doesn’t makes you run faster. She did not use anabolic steroids. It was pot,” she said. “Let her run.”

Let her run.

— Dr Janette Nesheiwat (@DoctorJanette) July 2, 2021


While the surgeon general doesn’t play an especially direct role in policymaking around drugs, the position has served as a key messaging vehicle for White House health platforms.

Under the Biden administration in 2021, for example, Surgeon General Vivek Murthy weighed in on marijuana decriminalization, saying “I don’t think that there is value to individuals or to society to lock people up for marijuana use. I don’t think that serves anybody well.”

Meanwhile, Jerome Adams, the surgeon general under the first Trump administration, issued an advisory in 2019 that warned about the risks of using marijuana, particularly for pregnant women and adolescents. It also contained misleading statements about the cannabis legalization movement.

So far, the president-elect’s cabinet choices have run the gamut as far as their cannabis positions are concerned.

For example, the next head of the Centers for Disease Control and Prevention (CDC) could be a vociferous opponent of marijuana reform if the former GOP Florida congressman that Trump selected for the job, Dave Weldon, is ultimately confirmed.

Trump’s pick to run the Food and Drug Administration (FDA) is also a medical marijuana skeptic, promoting claims that cannabis use is linked to cardiovascular issues and mental health problems for youth. He has also suggested that marijuana is a gateway drug.

In contrast, Robert F. Kennedy Jr., the president-elect’s choice for secretary of the U.S. Department of Health and Human Services (HHS) that oversees FDA, supports ending marijuana prohibition and legalizing certain psychedelics for therapeutic purposes.

Meanwhile, pro-legalization former Rep. Matt Gaetz (R-FL) was recently replaced by former Florida Attorney General Pam Bondi (R), who opposed medical cannabis legalization in the state, as Trump’s choice to for U.S. attorney general.

A non-governmental advisory body that Trump is putting together will have two familiar names helming the ship: Elon Musk and Vivek Ramaswamy. And while both are proponents of marijuana and psychedelics reform, giving hope to some reformers that the new entity will recommend scaling back the costly war on drugs, Ramaswamy has previously insisted on expanding the Drug Enforcement Administration (DEA).

Legalizing Medical Marijuana In Utah Helped Reduce Opioid Use By Pain Patients, Study Finds

 
 
 

A new study out of Ohio finds that a large majority of medical marijuana patients in the state say cannabis has reduced their use of prescription opioid painkillers as well as other, illicit drugs.

The survey of approximately 3,500 people—which was sent to state medical marijuana patients and caregivers through the Ohio Department of Commerce as well as shared online through social media—found that 77.5 percent agreed that marijuana reduced their need to use prescription painkillers. As for illicit drugs, 26.8 percent of respondents reported a diminished need to use.

Meanwhile, only small percentages of people disagreed that marijuana reduced their need to use prescription painkillers (1.7 percent) or illegal drugs (1.9 percent).

“Our results and those of previous studies display encouraging results about the potential benefits of using marijuana to reduce the use of painkillers and other illegal drugs,” says the new report, published as a preprint this month by Ohio State University law school’s Drug Enforcement and Policy Center.

“A large majority of respondents agreed that using marijuana reduced their use of prescription painkillers.”

Notably, those who used cannabis daily “were more likely to agree that using marijuana reduced their need to use prescription painkillers compared to those who used marijuana less than daily (daily = 80.54%, not daily = 70.14%),” wrote author Pete Leasure, a senior research associate at the Drug Enforcement and Policy Center.

Similar results were found regarding other illegal drug use. About 30.6 percent of daily cannabis users said marijuana reduced their need to use illicit drugs compared to about 17.5 percent of less-than-daily users.

In the first report to come out of the annual survey by DEPC @OSU_Law of current and potential Ohio #medicalmarijuana patients, we found that a large majority agreed that using #marijuana reduced their use of prescription painkillers.

Read report: https://t.co/MaXtc9K3Rdpic.twitter.com/NmvbhWLleM

— Drug Enforcement and Policy Center at Ohio State (@OSULawDEPC) July 16, 2024


The study acknowledges that given the non-random sampling method used, the data “may not be representative of all marijuana users (medical or non-medical).” But it nevertheless considers the results to point toward certain policy changes aimed at reducing overall harm.

“Several policy implications should be mentioned in light of these findings,” the report says. “First, if Ohio probation and parole offices include a prohibition of marijuana use for individuals with a history of opioid use, those offices may want to consider weighing the costs and benefits of removing those prohibitions (and thus any potential technical violations).”

“For evidence-based support, researchers could encourage probation and parole offices to assist with randomized controlled trials where some individuals are assigned to a marijuana prohibition and others are not assigned a marijuana prohibition,” the study suggests. “The success of either assignment could be judged by examining outcomes such as other drug use, technical violations, and or new crime commission.”

The report also notes some research showing that marijuana is associated with some negative health impacts.

“Therefore, even if more rigorous studies show that marijuana use reduces the use of prescription painkillers and other illegal drugs, more research will be needed to determine the efficacy of marijuana versus other treatments,” it says.

Moving marijuana from Schedule I to Schedule III of the federal Controlled Substances Act, Leasure notes, would make robust research “easier to conduct” and help reduce obstacles to conducting experimental trials.

The findings further the idea of a substitution effect whereby patients opt for cannabis instead of opioids or other drugs to treat pain, though nuances of the effect are still poorly understood.

Separate research published earlier this year that looked at opioid prescription and mortality rates in Oregon, for instance, found that nearby access to retail marijuana moderately reduced opioid prescriptions, though there was no corresponding drop in opioid-related deaths.

“We cannot know for sure why we see a reduction in prescription opioid use and not a mortality effect given our data constraints,” authors of that study told Marijuana Moment in an email about the report, “but a potential explanation could be that either the substitution effect is not large enough, or possibly, those who are most likely to succumb to opioid misuse are not making this particular substitution.”

Another report published recently in the journal BMJ Open compared medical marijuana and opioids for chronic non-cancer pain and found that cannabis “may be similarly effective and result in fewer discontinuations than opioids,” potentially offering comparable relief with a lower likelihood of adverse effects.

And federally funded study published in May concluded that even some cannabis terpenes may have pain-relieving effects. That research found that an injected dose of the compounds produced a “roughly equal” reduction in pain markers in mice when compared to a smaller dose of morphine. Terpenes also appeared to enhance the efficacy of morphine in mice when the two drugs were given in combination.

Another study, published late last year, found that marijuana and opioids were “equally efficacious” at mitigating pain intensity, but cannabis also provided more “holistic” relief, such as by improving sleep, focus and emotional wellbeing.

The same month, research published in the Journal of Dental Research found that pure CBD could alleviate acute dental pain about as well as an opioid formula commonly used in dentistry.

A study published last summer linked medical marijuana use to lower pain levels and reduced dependence on opioids and other prescription medications. Another, published by the American Medical Association (AMA) in February, found that chronic pain patients who received medical marijuana for longer than a month saw significant reductions in prescribed opioids.

About one in three chronic pain patients reported using cannabis as a treatment option, according to another AMA-published report last year. Most of that group said they used cannabis as a substitute for other pain medications, including opioids.

Other research published last year found that letting people buy CBD legally significantly reduced opioid prescription rates, leading to 6.6 percent to 8.1 percent fewer opioid prescriptions.

A 2022 research paper that analyzed Medicaid data on prescription drugs, meanwhile, found that legalizing marijuana for adult use was associated with “significant reductions” in the use of prescription drugs for the treatment of multiple conditions.

Pennsylvania Governor Pledges To Keep Up Marijuana Legalization Fight Despite Budget Setback

 
 
 

Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page